Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells

International Journal of Cancer

Volumn 103, Issue 2, 2003, Pages 177-184

  Primeau, Mélanie ^a   Gagnon, Jacynthe ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

5 aza 2 deoxycytydine; Breast cancer; Depsipeptide; DNA methylation; Gelsolin; Histone deacetylation; Maspin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DEPSIPEPTIDE; GELSOLIN; HISTONE DEACETYLASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DNA SYNTHESIS INHIBITION; DRUG POTENTIATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0037427805     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10789     Document Type: Article

References (44)

1. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genet 1999;21:163-7.
2. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000;16:168-74.
3. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145-54.
4. Hebbes TR, Thorne AW, Crane-Robinson C. A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J 1988;7:1395-402.
5. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1998;88:471-81.
6. Jones PL, Jan Veenstra GC, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genet 1998;19:187-91.
7. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM. Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
8. Antequera F, Macleod D, Bird AP. Specific protection of methylated CpGs in mammalian nuclei. Cell 1989;58:509.
9. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999;99:451.
10. Collingwood TN, Urnov FD, Wolffe AP. Nuclear receptors: Coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 1999;23:255-75.
11. Cameron EE, Bachman KE, Myöhánen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
12. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 1983;43:3493-6.
13. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1981;5:453-62.
14. Momparler RL, Bouchard J, Onetto N, Rivard GE. 5-aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leukemia Res 1984;8:181-5.
15. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8:358-68.
16. Momparler RL, Ayoub J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001;34:S111-5.
17. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
18. Momparler RL, Bouchard J, Samson J, Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine. Leuk Res 1985;9:1361-6.
19. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994;58:1579-83.
20. Rajgolikar G, Chan KK, Wang HC. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat 1998;51:29-38.
21. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor, Exp Cell Res 1998;241:126-33.
22. Domann FE, Rice JC, Hendrix MJC, Futscher BW. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 2000;85:805-10.
23. Mielnicki LM, Ying AM, Head KL, Asch HL, Asch BB. Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp Cell Res 1999;249:161-76.
24. Sheng, S, Pemberton P, Sager R. Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 1994;269:30988-93.
25. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJC, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 1996;93:11669-74.
26. Cunningham CC, Stossel TP, Kwiatkowski DJ. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 1991;251:1233-6.
27. Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treat 1999;55:179-88.
28. Fujita H, Okada F, Hamada J-I, Hosokawa M, Moriuchi T, Koya RC, Kuzumaki N. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer 2001;93:773-80.
29. Valeriote F, Lin H. Synergistic interaction of anticancer drugs. Cancer Chemother Rep 1975;59:895-9.
30. Momparler RL. In vitro systems for the evaluation of combination therapy. Pharmacol Ther 1980;8:21-5.
31. Ueda H, Nakajim H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 1994;47:301-10.
32. Ueda H, Manda T, Matsumoto S, Makumoto S, Nishigaki F, Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot 1994;47:315-23.
33. Garber K. Breaking the silence: The rise of epigenetic therapy. J Natl Cancer Inst 2002;94:874-5.
34. Bovenzi V, Momparler RL. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells. Cancer Chemother Pharmacol 2001;48:71-6.
35. Zhu W-G, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61:1327-33.
36. Zou Z, Anisowicz A, Hendrix MJC, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263:526-9.
37. Sager R, Sheng S, Pemberton P, Hendrix MJ. Maspin: A tumor suppressing serpin. Curr Top Microbiol Immunol 1996:213:51-64.
38. Seftor REB, Seftor AA, Sheng S, Pemberton PA, Sager R, Hendrix MJC. Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 1998;58:5681-5.
39. Lee HK, Driscoll D, Asch H, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999;40:14-9.
40. Asch HL, Head K, Dong Y. Natoli F, Winston JS, Connolly JS, Asch BB. Widespread loss of gelsolin in breast cancers of human, mice, and rats. Cancer Res 1996;56:4841-5.
41. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994;214:189-97.
42. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, et al. Sequential 5-aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ES0-1. J Immunother 2001;24:151-61.
43. Zhu W-G, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, Otterson GA. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer. Oncogene 2001;20:7787-96.
44. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER-α) by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 2001;61:7025-9.